司美格鲁肽与贝那鲁肽治疗2型糖尿病合并多囊卵巢综合征的对比研究

Comparison of semaglutide and beinaglutide in the treatment of type 2 diabetes mellitus with concurrent polycystic ovary syndrome

摘要:

目的 对比司美格鲁肽与贝那鲁肽治疗2型糖尿病（T2DM）合并多囊卵巢综合征（PCOS）的疗效及安全性。方法 选取2021年7月—2023年8月西北妇女儿童医院收治的153例T2DM合并PCOS患者为研究对象，按随机数字表法分为对照组（77例）和观察组（76例）。对照组注射贝那鲁肽注射液，观察组注射司美格鲁肽，两组治疗3个月后观察效果。比较两组治疗前后糖脂代谢指标、性激素与外周血因子及药物不良反应发生情况。结果 观察组治疗前后空腹血糖、餐后2 h血糖、胰岛素抵抗指数、胰岛β-细胞功能指数的差值均大于对照组（P <0.05）。观察组治疗前后三酰甘油、总胆固醇的差值均大于对照组（P <0.05）。观察组治疗前后睾酮、雌二醇、促黄体生成素、促卵泡生成激素的差值均大于对照组（P <0.05）。观察组治疗前后网膜素-1、单核细胞趋化蛋白-1、胰岛素样生长因子、摄食抑制因子-1的差值均大于对照组（P <0.05）。观察组、对照组总药物不良反应发生率分别为6.58%和5.19%，差异无统计学意义（P >0.05）。结论 与贝那鲁肽相比，司美格鲁肽治疗T2DM合并PCOS患者在改善糖脂代谢、激素水平及外周血因子分泌方面更具优势，且安全可靠。

Abstract:

Objective To compare the efficacy and safety of semaglutide and beinaglutide in the treatment of type 2 diabetes mellitus (T2DM) with concurrent polycystic ovary syndrome (PCOS).Methods A total of 153 T2DM patients with PCOS admitted to our hospital from July 2021 to August 2023 were selected, and were divided into the control group (77 cases) and the observation group (76 cases) according to the random number table method. The control group was administrated with beinaglutide injection, and the observation group was injected with semaglutide. Therapeutic effects were evaluated in both groups after three months of treatment. Changes in glucose and lipid metabolism indicators, sex hormones, peripheral blood factors, and adverse drug reactions were compared between the two groups before and after treatment.Results The differences in FPG, 2hPPG, HOMA-IR and HOMA-β levels before and after treatment in the observation group were higher than those in the control group (P < 0.05). The differences in TG and TC levels before and after treatment in the observation group were higher than those in the control group (P < 0.05). The differences in T, E₂, LH, and FSH levels before and after treatment in the observation group were higher than those in the control group (P < 0.05). The differences in OM-1, MCP-1, IGF, and NSF-1 levels before and after treatment in the observation group were also higher than those in the control group (P < 0.05). The overall incidence of adverse drug reactions was 6.58% in the observation group and 5.19% in the control group, with no statistically significant difference between the two groups (P > 0.05).Conclusion Compared with beinaglutide, semaglutide demonstrates greater advantages in improving glucose and lipid metabolism, hormone levels, and peripheral blood factors in patients with T2DM and PCOS, and is considered safe and well-tolerated.